These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8451010)

  • 1. Controlled study of the antiparkinsonian activity and tolerability of cabergoline.
    Hutton JT; Morris JL; Brewer MA
    Neurology; 1993 Mar; 43(3 Pt 1):613-6. PubMed ID: 8451010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
    Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD
    Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.
    Hutton JT; Koller WC; Ahlskog JE; Pahwa R; Hurtig HI; Stern MB; Hiner BC; Lieberman A; Pfeiffer RF; Rodnitzky RL; Waters CH; Muenter MD; Adler CH; Morris JL
    Neurology; 1996 Apr; 46(4):1062-5. PubMed ID: 8780092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.
    Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD; Dubini A; Orlando N; Grimaldi R
    Neurology; 1997 Feb; 48(2):363-8. PubMed ID: 9040722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.
    Lieberman A; Imke S; Muenter M; Wheeler K; Ahlskog JE; Matsumoto JY; Maraganore DM; Wright KF; Schoenfelder J
    Neurology; 1993 Oct; 43(10):1981-4. PubMed ID: 8105422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations.
    Steiger MJ; El-Debas T; Anderson T; Findley LJ; Marsden CD
    J Neurol; 1996 Jan; 243(1):68-72. PubMed ID: 8869390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect.
    Ahlskog JE; Wright KF; Muenter MD; Adler CH
    Clin Neuropharmacol; 1996 Jun; 19(3):202-12. PubMed ID: 8726539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R; Schechtman E; Nisipeanu P
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline.
    Ahlskog JE; Muenter MD; Maraganore DM; Matsumoto JY; Lieberman A; Wright KF; Wheeler K
    Arch Neurol; 1994 Dec; 51(12):1236-41. PubMed ID: 7986180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effect of cabergoline, new long-lasting D2 agonist in the treatment of Parkinson's disease.
    Rabey JM; Nissipeanu P; Inzelberg R; Korczyn AD
    Clin Neuropharmacol; 1994 Jun; 17(3):286-93. PubMed ID: 9316674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
    Marsden CD
    Drugs; 1998; 55 Suppl 1():17-22. PubMed ID: 9483166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist.
    Porter MC; Appiah-Kubf LS; Chaudhuri KR
    Int J Clin Pract; 2002; 56(6):468-74. PubMed ID: 12166546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabergoline : a review of its use in the treatment of Parkinson's disease.
    Curran MP; Perry CM
    Drugs; 2004; 64(18):2125-41. PubMed ID: 15341508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients.
    Del Dotto P; Colzi A; Pardini C; Lucetti C; Dubini A; Grimaldi R; Bonuccelli U
    J Neural Transm Suppl; 1995; 45():259-65. PubMed ID: 8748633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabergoline in Parkinson's disease complicated by motor fluctuations.
    Geminiani G; Fetoni V; Genitrini S; Giovannini P; Tamma F; Caraceni T
    Mov Disord; 1996 Sep; 11(5):495-500. PubMed ID: 8866490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cabergoline in the treatment of Parkinson's disease].
    Pastor P; Tolosa E
    Neurologia; 2003 May; 18(4):202-9. PubMed ID: 12721865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabergoline in Parkinson's disease: long-term follow-up.
    Lera G; Vaamonde J; Rodriguez M; Obeso JA
    Neurology; 1993 Dec; 43(12):2587-90. PubMed ID: 7902970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease.
    Inzelberg R; Nisipeanu P; Rabey MJ; Korczyn AD
    Mov Disord; 1995 Sep; 10(5):604-7. PubMed ID: 8552112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.